Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies

被引：100

作者：

Shojaei, Farbod ^{[1
]}

Ferrara, Napoleone ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

DRUG RESISTANCE UPDATES | 2008年 / 11卷 / 06期

关键词：

Tumor angiogenesis; VEGF; Anti-VEGF; Stromal cells; CD11b+Gr1+cells; Tumor-associated endothelial cells; Endothelial progenitor cells;

D O I：

10.1016/j.drup.2008.09.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Angiogenesis is critical for growth of many tumor types and the development of anti-angiogenic agents opened a new era in cancer therapy. However, similar to other anti-cancer therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in cancer patients leading to disease recurrence. Recent studies in several experimental models suggest that both tumor and non-tumor (stromal) cell types may be involved in the reduced responsiveness to the treatments. The current review focuses on the role of stromal cells in tumor growth and in refractoriness to anti-VEGF treatment. (C) 2008 Elsevier Ltd. All rights reserved.

引用

收藏

页码：219 / 230

页数：12

相关论文

共 175 条

[1] Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells [J].

Ahn, G-One ;

Brown, J. Martin .

CANCER CELL, 2008, 13 (03) :193-205

[2] VASCULAR REACTIONS OF NORMAL AND MALIGNANT TISSUES INVIVO .1. VASCULAR REACTIONS OF MICE TO WOUNDS AND TO NORMAL AND NEOPLASTIC TRANSPLANTS [J].

ALGIRE, GH ;

CHALKLEY, HW .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1945, 6 (01) :73-85

[3]

Almand B, 2000, CLIN CANCER RES, V6, P1755

[4] Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer [J].

Almand, B ;

Clark, JI ;

Nikitina, E ;

van Beynen, J ;

English, NR ;

Knight, SC ;

Carbone, DP ;

Gabrilovich, DI .

JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :678-689

[5] Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors [J].

Baluk, P ;

Morikawa, S ;

Haskell, A ;

Mancuso, M ;

McDonald, DM .

AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (05) :1801-1815

[6]

Banchereau J, 2001, CANCER RES, V61, P6451

[7] Effects of angiogenesis inhibitors on multistage carcinogenesis in mice [J].

Bergers, G ;

Javaherian, K ;

Lo, KM ;

Folkman, J ;

Hanahan, D .

SCIENCE, 1999, 284 (5415) :808-812

[8] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[9] Dendritic cells and cytokines in human inflammatory and autoimmune diseases [J].

Blanco, Patrick ;

Palucka, A. Karolina ;

Pascual, Virginia ;

Banchereau, Jacques .

CYTOKINE & GROWTH FACTOR REVIEWS, 2008, 19 (01) :41-52

[10] Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate [J].

Boissel, N ;

Rousselot, P ;

Raffoux, E ;

Cayuela, JM ;

Maarek, O ;

Charron, D ;

Degos, L ;

Dombret, H ;

Toubert, A ;

Rea, D .

LEUKEMIA, 2004, 18 (10) :1656-1661

← 1 2 3 4 5 6 7 8 9 10 →